Dr Reddy's Laboratories PE Ratio 2010-2024 | RDY

Current and historical p/e ratio for Dr Reddy's Laboratories (RDY) from 2010 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Dr Reddy's Laboratories PE ratio as of November 01, 2024 is 18.57.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Dr Reddy's Laboratories PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2024-10-31 73.90 18.48
2024-06-30 75.74 $4.00 18.93
2024-03-31 72.92 $4.03 18.09
2023-12-31 69.17 $3.79 18.25
2023-09-30 66.47 $3.71 17.92
2023-06-30 62.30 $3.46 18.01
2023-03-31 56.20 $3.33 16.88
2022-12-31 51.09 $2.70 18.92
2022-09-30 51.67 $2.36 21.89
2022-06-30 54.28 $2.34 23.20
2022-03-31 54.61 $1.90 28.74
2021-12-31 64.10 $2.29 27.99
2021-09-30 63.83 $1.74 36.69
2021-06-30 71.44 $1.56 45.79
2021-03-31 59.66 $1.56 38.24
2020-12-31 69.28 $1.71 40.52
2020-09-30 67.60 $1.21 55.87
2020-06-30 51.19 $1.52 33.68
2020-03-31 38.94 $1.64 23.75
2019-12-31 39.19 $1.41 27.79
2019-09-30 36.59 $2.30 15.91
2019-06-30 35.93 $1.79 20.08
2019-03-31 38.84 $1.61 24.12
2018-12-31 36.15 $1.51 23.94
2018-09-30 33.18 $1.42 23.37
2018-06-30 30.61 $1.26 24.29
2018-03-31 31.08 $0.92 33.78
2017-12-31 35.71 $0.93 38.39
2017-09-30 33.92 $1.03 32.93
2017-06-30 39.76 $1.04 38.23
2017-03-31 37.88 $1.09 34.76
2016-12-31 42.72 $0.87 49.11
2016-09-30 43.80 $0.96 45.62
2016-06-30 48.07 $1.33 36.14
2016-03-31 42.40 $1.80 23.56
2015-12-31 43.44 $2.22 19.57
2015-09-30 59.97 $2.24 26.77
2015-06-30 51.63 $2.14 24.13
2015-03-31 53.29 $2.10 25.38
2014-12-31 47.09 $2.08 22.64
2014-09-30 49.05 $2.14 22.92
2014-06-30 40.01 $2.25 17.78
2014-03-31 40.71 $2.11 19.29
2013-12-31 38.05 $2.24 16.98
2013-09-30 35.04 $2.05 17.09
2013-06-30 34.82 $1.90 18.33
2013-03-31 29.79 $1.90 15.68
2012-12-31 30.65 $1.70 18.03
2012-09-30 28.42 $1.90 14.96
2012-06-30 27.33 $1.80 15.18
2012-03-31 31.57 $1.75 18.04
2011-12-31 26.88 $1.75 15.36
2011-09-30 27.22 $1.55 17.56
2011-06-30 31.36 $1.55 20.23
2011-03-31 33.20 $1.50 22.14
2010-12-31 32.90 $1.30 25.31
2010-09-30 28.68 $0.20 143.41
2010-06-30 27.46 $0.10 274.62
2010-03-31 24.94 $0.10 249.37
2009-12-31 21.39 $-1.20 0.00
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $12.399B $3.350B
Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.902B 7.10
BridgeBio Pharma (BBIO) United States $4.791B 0.00
Bausch Health Cos (BHC) Canada $3.597B 2.61
Amphastar Pharmaceuticals (AMPH) United States $2.469B 13.82
Supernus Pharmaceuticals (SUPN) United States $1.872B 377.44
Taysha Gene Therapies (TSHA) United States $0.314B 51.00
Personalis (PSNL) United States $0.270B 0.00
Assembly Biosciences (ASMB) United States $0.107B 0.00
Acasti Pharma (GRCE) Canada $0.031B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00